CHICAGO — Belantamab mafodotin monotherapy did not significantly extend PFS compared with the combination of pomalidomide and dexamethasone among adults with relapsed or refractory multiple myeloma, phase 3 study results showed.
However, data from the randomized trial presented at ASCO Annual Meeting suggest that single-agent treatment with belantamab mafodotin (Blenrep, GSK) may have greater durability than the pomalidomide-dexamethasone regimen, investigators noted.
“While this study did not meet its primary objective or demonstrating PFS superiority, single-agent [belantamab
